Verimatrix XTD Wins Top Infosec Innovators Award for Mobile App Security
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced it was named a winner of the Editor’s Choice award for Mobile App Security in Cyber Defense Magazine’s (CDM) Top Infosec Innovators Awards.
Continually honored with industry accolades recognizing the app shielding innovations within its Verimatrix XTD Enterprise Suite, the company provides some of the world’s most discerning mobile app developers with the latest security technologies to consistently protect their app-centric businesses. Verimatrix XTD stands as the go-to security solution for organizations looking to proactively protect vital mobile apps from today’s wide range of threats such as supply chain attacks, screen overlays, application repackaging, illicit modification or tampering, man-in-the-device attacks, and more. Its advanced obfuscation techniques as well as its threat detection and response capabilities using AI/ML, put XTD into an enterprise class like few others.
"Verimatrix embodies three major features we judges look for with the potential to become winners: understanding tomorrow’s threats, today, providing a cost-effective solution and innovating in unexpected ways that can help mitigate cyber risk and get one step ahead of the next breach," said Gary S. Miliefsky, Publisher of Cyber Defense Magazine.
“We are honored that XTD received the Editor’s Choice recognition in this year’s CDM Top Infosec Innovators Awards program,” said Asaf Ashkenazi, CEO at Verimatrix. “Verimatrix is committed to providing its mobile app customers with the latest innovations designed to powerfully protect against today’s complex attacks. This award underscores the mobile app security expertise that Verimatrix offers through a team of highly dedicated engineers and experts who specialize this field.”
For more information on the Verimatrix XTD Enterprise Suite, visit www.verimatrix.com/cybersecurity.
A full list of the 2024 Top Infosec Innovators Award winners is available at:
https://cyberdefenseawards.com/top-infosec-innovators-for-2024
About Cyber Defense Awards
This is Cyber Defense Magazine's 12th year of honoring cybersecurity innovators, in this case the Top Global CISOs for 2024, on our Cyber Defense Awards platform. In this competition, judges for these and other prestigious awards includes cybersecurity industry veterans, trailblazers and market makers Gary Miliefsky of CDMG, Dr. Lindsey Polley de Lopez of VentureScope, Katie Gray of In-Q-Tel, Robert R. Ackerman Jr. of Allegis Cyber, Dino Boukouris of AltitudeCyber and with much appreciation to emeritus judges Robert Herjavec of Cyderes, Dr. Peter Stephenson of CDMG and David DeWalt of NightDragon. Top InfoSec Innovators for 2024 is found here: https://cyberdefenseawards.com/top-infosec-innovators-for-2024 and download The Black Unicorn Report for 2024: https://cyberdefenseawards.com/the-black-unicorn-report-for-2024 and Top Global CISOs Winners for 2024, here: https://cyberdefenseawards.com/top-global-cisos-winners-for-2024.
About Cyber Defense Magazine
Cyber Defense Magazine was founded in 2012 by Gary S. Miliefsky, a globally recognized cyber security thought leader, inventor and entrepreneur and continues to be the premier source of IT Security information. We are managed and published by and for ethical, honest, passionate information security professionals. Our mission is to share cutting-edge knowledge, real-world stories and awards on the best ideas, products and services in the information technology industry. We deliver electronic magazines every month online for free, and limited special editions exclusively for the RSA, BlackHat and Cyber Defense Conferences. Cyber Defense Magazine is a proud member of the Cyber Defense Media Group. Learn more at http://www.cyberdefensemagazine.com.
About Verimatrix
Verimatrix (Euronext Paris: VMX, FR0010291245) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure premium movies, live streaming sports, sensitive financial and healthcare data, mission-critical mobile applications, and much more. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112296465/en/
Contacts
Verimatrix Investor Contact:
Jean-François Labadie, Chief Financial Officer
finance@verimatrix.com
SEITOSEI.ACTIFIN
Mathilde Guillemot-Costes
mathilde.guillemot@seitosei-actifin.com
Michael Scholze
Michael.scholze@seitosei-actifin.com
Verimatrix Media Contact:
Matthew Zintel
matthew.zintel@zintelpr.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press Release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press Release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press Release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press Release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom